Update on the use of cinacalcet in the management of primary hyperparathyroidism

Journal of Endocrinological Investigation

Volumn 35, Issue 1, 2012, Pages 90-95

  Marcocci, C ^a   Cetani, F ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Calcium sensing receptor; Hypercalcemia; Hyperparathyroidism; Parathyroid carcinoma; Persistent primary

Indexed keywords

CALCIUM SENSING RECEPTOR; CINACALCET; TECALCET;

ARTHRALGIA; CALCIUM BLOOD LEVEL; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; HEADACHE; HUMAN; HYPERCALCEMIA; LONG TERM CARE; MULTIPLE ENDOCRINE NEOPLASIA; MYALGIA; NAUSEA; PARATHYROID CARCINOMA; PRIMARY HYPERPARATHYROIDISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; UPPER RESPIRATORY TRACT INFECTION;

DISEASE MANAGEMENT; HUMANS; HYPERPARATHYROIDISM, PRIMARY; NAPHTHALENES;

EID: 84861963690     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8112     Document Type: Short Survey

References (39)

1. Bilezikian JP. Primary hyperparathyroidism. In: DeGroot LJ, ed. Endotext.org http://www.endotext.org/parathyroid/parathyroid5/parathyroidframe5. htm (accessed March 7, 2011)
2. Khan A, Grey A, Shoback D. Medical management of asymptomatic primary hyperparathyrodism: Proceedings of the third international workshp. J Clin Endocrinol Metab 2009, 94: 373-81.
3. Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004, 308: 627-35. (Pubitemid 38134225)
4. Nemeth EF, Fox J. Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab 1999, 10: 66-71. (Pubitemid 29287825)
5. Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci U S A 1998, 95: 4040-5. (Pubitemid 28173250)
6. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Cobum JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000, 58: 436-45. (Pubitemid 30429892)
7. US Food and Drug Administration. Sensipar (cinacalcet) tablets. www.accessdata.tda.gov/dnjgsatfda-docs/label/2008/021688s008Ibl.pdf
8. Colloton M, Shatzen E, Miller G, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005, 67: 467-76. (Pubitemid 40139838)
9. Kawata T, Imanishi Y, Kobayashi K, et al. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism. Eur J Endocrinol 2005, 153: 587-94. (Pubitemid 41556286)
10. Ohashi N, Uematsu T, Nagashima S, et al. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. Br J Clin Pharmacol 2004, 57: 726-34. (Pubitemid 38748040)
11. Kumar GN, Sproul C, Poppe L, et al. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. Drug Metab Dispos 2004, 32: 1491-500. (Pubitemid 39564571)
12. Dong BJ. Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther 2005, 27: 1725-51. (Pubitemid 41815225)
13. Padhi D, Salfi M, Harris RZ. The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals. Am J Ther 2007, 14: 235-40. (Pubitemid 46791558)
14. Padhi D, Salfi M, Emery M. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents: a randomized, open-label, crossover, single-centre study in healthy volunteers. Drugs R D 2008, 9: 335-43.
15. Padhi D, Harris RZ, Salfi M, Noveck RJ, Sullivan JT. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment: phase I, open-label, parallel-group, single-dose, single-centre study. Clin Drug Investig 2008, 28: 635-43.
16. Nakashima D, Takama H, Ogasawara Y, et al. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and dinical studies. J Clin Pharmacol 2007, 47: 1311-9. (Pubitemid 47459660)
17. Silverberg SJ, Bone HG 3rd, Marriott TB, et al. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997, 337: 1506-10. (Pubitemid 27495776)
18. Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003, 88: 5644-9. (Pubitemid 38033028)
19. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005, 90: 135-41. (Pubitemid 40116646)
20. Peacock M, Bolognese MA, Borofsky M, et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometry outcomes in a five-year study. J Clin Endocrinol Metab 2009, 94: 4860-7.
21. Cetani F, Saponaro F, Banti C, et al. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling. J Endocrinol Invest 2011, Sep 30 [Epub ahead of print].
22. Zanocco K, Angelos P, Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery 2006, 140: 874-81.
23. Horjus C, Groot I, Telting D, et al. Cinacalcet for hyperparathyroidism in pregnancy and puerperium. J Pediatr Endocrinol Metab 2009, 22: 741-9.
24. Sloand JA, Shelly MA. Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinacalcet hydrochloride. Am J Kidney Dis 2006, 48: 832-7. (Pubitemid 44585093)
25. Akinci B, Comlekci A, Tankurt E. Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis. Exp Clin Endocrinol Diabetes 2009, 117: 142-5.
26. Fanari Z, Kadikoy H, Haque W, Pacha O, Abdellatif A. Medical management of primary hyperparathyroidism with concomitant multiple myeloma. Inter Med 2010, 49: 581-4.
27. Dvorak MM, Chen TH, Orwoll B, et al. Constitutive activity of the osteoblast Ca2+-sensing receptor promotes loss of cancellous bone. Endocrinology 2007, 148: 3156-63. (Pubitemid 46996999)
28. Vezzoli G, Terranegra A, Arcidiacono T, et al. R990G polymorphism of calcium sensing receptor does produce a gain-of-function and predispose to primary hypercalciuria. Kidney Int 2007, 71: 1155-62. (Pubitemid 46809131)
29. Rothe HM, Shapiro WB, Sun WY, Chou SY. Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCL Pharmacogenet. Genomics 2005, 15: 29-34. (Pubitemid 43205524)
30. Rothe HM, Shapiro WB, Sun WY, Matalon A. CaSR polymorphism Arg990Gly and response to calcimimetic agents in end-stage kidney disease patients with secondary hyperparathyroidism and in cell culture. Personalized Med 2008, 5: 109-16. (Pubitemid 351586526)
31. Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP. Parathyroid carcinoma. J Bone Miner Res 2008, 23: 1869-80.
32. Silverberg SJ, Faiman C, Bilezikian JP, et al. The effect of cinacalcet HCl (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary HPT after PTx. J Bone Miner Res 2003, 18 (Suppl 2): S171 (abstract).
33. Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 2007, 92: 3803-8. (Pubitemid 47607626)
34. Marcocci C, Chanson P, Shoback D, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 2009, 94: 2766-72.
35. Falchetti A, Cilotti A, Vaggelli L, et al. A patient with MEN1-associate hyperparathyroidism, responsive to cinacalcet. Nat Clin Pract Endocrinol Metab 2008, 4: 351-7. (Pubitemid 351733458)
36. Moyes VJ, Monson JP, Chew SL, Akker SA. Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism. Int J Endocrinol 2010, 2010: 906163.
37. Timmers HJ, Karperien M, Hamdy NA, De Boer H, Hermus AR. Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. J Intern Med 2006, 260: 177-82. (Pubitemid 44051343)
38. Reh CM, Hendy GN, Cole DE, Jeandron DD. Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. J Clin Endocrinol Metab 2011, 96: E707-12.
39. Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004, 89: 3319-25. (Pubitemid 38951898)